Clinuvel Pharmaceuticals Ltd
ASX:CUV

Watchlist Manager
Clinuvel Pharmaceuticals Ltd Logo
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Watchlist
Price: 10.69 AUD 0.28% Market Closed
Market Cap: 535.8m AUD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+137%
Revenue
Forecast
+24%
Operating Income
Forecast
+25%
Net Income
Forecast
+25%

Wall Street
Price Targets

CUV Price Targets Summary
Clinuvel Pharmaceuticals Ltd

Wall Street analysts forecast CUV stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CUV is 25.35 AUD with a low forecast of 14.14 AUD and a high forecast of 39.11 AUD.

CUV Lowest Forecast
Wall Street Target
14.14 AUD
32% Upside
CUV Average Forecast
Wall Street Target
25.35 AUD
137% Upside
CUV Highest Forecast
Wall Street Target
39.11 AUD
266% Upside
Lowest
Price Target
14.14 AUD
32% Upside
Average
Price Target
25.35 AUD
137% Upside
Highest
Price Target
39.11 AUD
266% Upside
Clinuvel Pharmaceuticals Ltd Competitors:
Price Targets
ZNTL
Zentalis Pharmaceuticals Inc
305% Upside
RCKT
Rocket Pharmaceuticals Inc
146% Upside
H
2142
Hbm Holdings Ltd
17% Downside
M
MDXH
MDxHealth SA
61% Upside
ZNTL
Zentalis Pharmaceuticals Inc
305% Upside
RCKT
Rocket Pharmaceuticals Inc
146% Upside
H
2142
Hbm Holdings Ltd
17% Downside
M
MDXH
MDxHealth SA
61% Upside
MCRB
Seres Therapeutics Inc
136% Upside
NTLA
Intellia Therapeutics Inc
196% Upside
IMMX
Immix Biopharma Inc
222% Upside

Revenue
Forecast

Revenue Estimate
Clinuvel Pharmaceuticals Ltd

For the last 13 years the compound annual growth rate for Clinuvel Pharmaceuticals Ltd's revenue is 39%. The projected CAGR for the next 3 years is 24%.

39%
Past Growth
24%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Clinuvel Pharmaceuticals Ltd

The compound annual growth rate of Clinuvel Pharmaceuticals Ltd's operating income for the next 3 years is 25%.

N/A
Past Growth
25%
Estimated Growth
Estimates Accuracy
8%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Clinuvel Pharmaceuticals Ltd

The compound annual growth rate of Clinuvel Pharmaceuticals Ltd's net income for the next 3 years is 25%.

N/A
Past Growth
25%
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

See Also

Summary
CUV intrinsic value, competitors valuation, and company profile.
DCF Valuation
CUV stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CUV stock valuation using valuation multiples.
Wall Street Estimates
CUV price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CUV stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CUV's stock price target?
Price Target
25.35 AUD

According to Wall Street analysts, the average 1-year price target for CUV is 25.35 AUD with a low forecast of 14.14 AUD and a high forecast of 39.11 AUD.

What is Clinuvel Pharmaceuticals Ltd's Revenue forecast?
Projected CAGR
24%

For the last 13 years the compound annual growth rate for Clinuvel Pharmaceuticals Ltd's revenue is 39%. The projected CAGR for the next 3 years is 24%.

What is Clinuvel Pharmaceuticals Ltd's Operating Income forecast?
Projected CAGR
25%

The compound annual growth rate of Clinuvel Pharmaceuticals Ltd's operating income for the next 3 years is 25%.

What is Clinuvel Pharmaceuticals Ltd's Net Income forecast?
Projected CAGR
25%

The compound annual growth rate of Clinuvel Pharmaceuticals Ltd's net income for the next 3 years is 25%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 281,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.